An observational study in Preeclampsia, Heart Failure Preserved Ejection Fraction and Hypertension, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Vanderbilt University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.
Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 16th largest by planned enrollment of the 69 observational ones that give a count, is one of 13 that started in 2025, is one of 69 observational ones, reaches primary completion later than 69 of the 77 other live ones, and was the 194th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
Texas Southern University · Sites in United States
Ages 18–45 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 24 · Phase 3 15 · Phase 4 31
First in 2000; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Median enrollment 89 across the 161 interventional studies, 125 across the 69 observational. Of the 126 that completed or were terminated, 54 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 230 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Vanderbilt University Medical Center has 2 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
26 of the studies in Pre-Eclampsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222852Phase 3Women and Infants Hospital of Rhode IslandCardiovascular Protection After Preeclampsia With Enalapril | 2027-10-15 |
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT05676476University of Alabama at BirminghamThe ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. | 2026-12 |
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT06523569Northwestern UniversityMobile Health Interventions to Prevent Heart Disease After Hypertensive Disorders of Pregnancy | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 230 studies in Pre-Eclampsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Though cardiovascular disease (CVD) is the leading cause of mortality in women, traditional epidemiology in this area has focused on later life, when cardiometabolic risk has already exacted a cumulative toll on the vascular system. Recent data from the investigators and others has highlighted pregnancy as a unique, early moment of cardiovascular stress in young women that may "unmask" CVD propensity. It is unclear if PreE simply represents a "failed stress test" or directly contributes to the pathophysiology of future CVD. While mechanistic studies have largely been the purview of model-based studies, endothelial dysfunction has emerged as central to the pathogenesis of both PreE and peripartum cardiac dysfunction. Indeed, biomarkers of endothelial dysfunction and angiogenic imbalance during pregnancy have been shown to remain elevated at least 6 months post-partum. Moreover, peri-partum endothelial dysfunction can persist for years post-delivery and remains a significant risk factor for CVD (even after adjustment for other traditional risk factors). While these findings suggest that PreE-associated endothelial dysfunction and inflammation may contribute to early myocardial dysfunction that presages HF risk decades before its onset, the modifiable epidemiology of PreE-associated LVDD, including potential mechanisms of risk, remains unclear, limited by lack of precision molecular phenotypes accessible in a large number of American women across race. Ultimately, understanding the epidemiology and pathobiology of PreE-associated myocardial dysfunction affords a unique opportunity to identify women at risk with a longer lead-time for risk factor modification to interrupt CVD.
The investigators hypothesize that persistent structural-functional myocardial alterations after PreE are linked to pre- and post-gravid cardiometabolic risk factors (SA1), functional and hemodynamic impairment (SA2) and select pathways of vascular and inflammatory stress relevant to HF risk (SA3). Despite extensive study on the role of inflammation/ischemia in PreE, there have been no large studies connecting these phenotypes with early PP functional response and biochemical alterations, a key barrier to designing studies for improving CVD/HF in women.
SA1: To identify pregnancy-specific clinical factors related to postpartum HFpEF phenotypes Clinical Implication: Improve identification of women at highest risk for developing post-PreE LV diastolic dysfunction (a harbinger of HFpEF).
SA2: To define functional and hemodynamic signatures of early HFpEF due to preeclampsia
Clinical Implication: Identify women at highest risk for developing early HFpEF.
SA3: To identify shared pathophysiologic mechanistic pathways for PreE-associated HFpEF Clinical Implication: Identify targetable pathways for post-PreE cardiac dysfunction that may prevent/ delay HFpEF development.
Participants will be identified by daily electronic health record (EHR) search with American College of Obstetricians and Gynecologists (ACOG) criteria for PreE. The investigators will begin recruitment of participants in both their third trimester, as well as at admission to the Labor and Delivery Service. The investigators may consent and enroll patients in the study prior to being admitted, to allow ample time to consider participation. Patients admitted to the Labor and Delivery service will be identified as being diagnosed with PreE using a checklist, with supervision of a board-certified obstetrician with NIH- funded experience in obstetric research.
Participants will be recruited and enrolled until the investigators reach the goal of 250 cases and 250 controls. The subject will first be prescreened for eligibility. The study team will then approach the care team of the subject and request permission to approach the subject about participation in the study. Once permission has been granted the study team will then approach the subject.
Once the study team is in contact with the potential participant (and it has been assessed that they meet study eligibility), they will receive a complete explanation of the protocol, and the informed consent will be reviewed with them. The consent form will clearly state that participants may end participation at any time without prejudice, and this is emphasized to the subject. In particular, participants who receive their health care at Vanderbilt University Medical Center will be reassured that their decision to decline participation will in no way affect their medical treatment.
In order to assess the capacity to consent in critically ill patients, a member of the study team will ask the participants about their understanding/awareness of their condition and their perceived reason for their hospitalization. If the study team suspect impaired competence based on subject's responses, the subject will be excluded from the study.
Enrollment. For this study, the investigators will leverage the multidisciplinary cardio-obstetrics clinical research team, a collaboration between the Cardiology Division, Dept of Medicine and Maternal Fetal Medicine, Dept of Obstetrics and Gynecology established and led by PI Lindley. The team is designed to deploy high-success methods to recruit, schedule, follow-up and retain participants. At Vanderbilt University Hospital, there are >5000 deliveries per year; of these, 22% women develop hypertensive disorders of pregnancy. The investigators have previously been very successful in recruiting patients with PreE from both the Women's Health Clinic, and the inpatient Labor and Delivery service, and anticipate no difficulties with recruitment. PI Lindley has previously successfully recruited over 350 postpartum women with hypertensive disorders of pregnancy for prospective clinical studies and has previously successfully completed a pilot study of postpartum exercise stress testing at 12-16 weeks after delivery in 53 women with PreE, with 49% racial/ethnic minority women recruited and retained. For this study, the goal is that \~25% of enrolled participants would self-identify as black.
Dr. Lindley is also the PI on the 'Multi-Omics for Maternal Health after Preeclampsia' (MOM-Health) study (IRB # 232160). In the event that participants choose to co-enroll in both studies, the investigators may use data from MOM-Health and vice versa to reduce duplication of study procedures where there may be overlap (ex: Biospecimen collection, surveys etc.). Study staff will strive to match up co-enrolled participants' follow-up visits so that they may be homogenized into one visit.
Surveys and questionnaires (At enrollment/ Within \~48 hr. of delivery, approximately 12-16 weeks postpartum, and approximately 1 year postpartum): The questionnaires regarding demographics, medical history, breastfeeding and reproductive health, substance use, mental health and functional status will be obtained.
Cardiovascular Assessment (within approximately 48 hr. of delivery, approximately 12-16 weeks postpartum, and approximately 1 year postpartum): Participants will have vital signs (blood pressure, heart rate, weight) obtained at each visit. In addition, either at enrollment during the third trimester, or prior to discharge from delivery hospitalization, participants will be given an at home blood pressure monitor with instructions on how to use the blood pressure cuff and report results. Participants will be asked to take their blood pressure up to twice per day, every day (morning and afternoon/evening), with instructions to retest within 15 minutes if an elevated blood pressure is detected. Blood pressure readings will be self-recorded, using an EHR log provided to the subject (My Health at Vanderbilt blood pressure flowsheet). Alternatively, participants will use a Bluetooth enabled device that allows the blood pressure readings to be directly transmitted into the EHR, viewable by their providers and study staff. Participants who forget to measure their blood pressures will be gently reminded to continue to do so. Participants will not be asked to return the cuff (it is theirs to keep). If they lose the cuff, the investigators will give them a replacement.
Brachial artery reactivity testing (BART) (approximately 12-16 weeks postpartum and approximately 1 year postpartum): the investigators will perform BART on all participants to assess PP endothelial function. Technique: Patients will be placed in the supine position with a blood pressure cuff in place on the upper arm. The brachial artery will be imaged with ultrasound. Baseline flow will be estimated by pulsed Doppler. Subsequently, the cuff will be inflated to 50 mmHg above systolic pressure, then released. Pulsed Doppler measurements of the brachial artery will be recorded every 30 seconds until 2 minutes after release of occlusion. Flow mediated dilatation (FMD) will be assessed by maximal percent change from baseline to post-inflation velocity. The investigators have experience in acquisition of these measures during exercise in the PP setting, increasing feasibility.
Rest echocardiography (within approximately 48 hr. of delivery, approximately 12-16 weeks postpartum, and approximately 1 year postpartum): Initial echocardiography will be obtained at the bedside on the Labor and Delivery unit at enrollment (within approximately 48 hours of delivery) and again at approximately 12-16 weeks postpartum, and approximately 1 year postpartum.
Perturbational echocardiography (approximately 12-16 weeks postpartum and approximately 1 year postpartum): In addition to rest echocardiography, the investigators will perform two sets of perturbations aimed at providing a volume challenge (leg lift) and assessing response to exercise (CPET). The investigators will be following ACC/AHA guidelines for performance/termination of exercise testing, and as such, these measures are safe in the postpartum setting.
Biomarkers of placental vascular dysfunction and inflammatory stress (within approximately 48 hr. of delivery, approximately 12- 16 weeks postpartum, and approximately 1 year postpartum): Within approximately 48 hours of delivery, approximately 12- 16 weeks postpartum, and approximately1 year postpartum, the investigators will collect up to 50 ml of maternal venous blood which will be centrifuged and frozen at -80°C until use. As in the preliminary work, sFLT-1 and PIGF will be analyzed by ELISA. The investigators have also enlisted a less targeted approach to provide broader insight into inflammation, microvascular ischemia and endothelial dysfunction that characterize PreE-induced HFpEF, using the Olink system. The obtained placental, cord blood and urine samples obtained at delivery will be stored as resources in the cardiovascular biobank for future investigative studies by the scientific community to increase the impact of the investment of the participants. Urine samples will be obtained at each additional follow-up. Although no immediate genetic testing is planned for the specimens collected in this study, studies relating to genetic risk factors for cardiovascular disease/hypertensive disorders of pregnancy may perform genetic testing on these specimens in the future.
The population will include women who can biologically bear children. Traditionally, women (especially minorities) have been under-represented in studies to characterize HFpEF predisposition, despite their disproportionate risk. VUMC is located in the Southeast and cares for a disproportionate number of Black pregnant women with Preeclampsia. Given the increased risk of PreE in Black populations, we strive to maximize enrollment of Black women in our study, with a target of at least 25% of the enrolled subjects self-identifying as Black. Our targeted enrollment of Black women addresses clinical and investigative gaps in this population at high short and long-term CV risk following a preeclamptic pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Controls
1. Enrolling controls who meet the same inclusion/exclusion criteria, except they do not have preeclampsia and do not have pre-existing diabetes or chronic hypertension.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Controls who meet the same inclusion/exclusion criteria, except they do not have preeclampsia and do not have pre-existing diabetes or chronic hypertension.
Preeclamptic participants who meet the inclusion/exclusion criteria
To measure relation between postpartum subclinical LV diastolic dysfunction and pregnancy-specific risk factors in 250 women with PreE and 250 normotensive women through echocardiographic imaging.
Pre-pregnancy risk factors (HTN, DM, delivery body mass index \[BMI\], age), pregnancy-specific risk factors (PreE severity, gestational age at delivery, gravidity, GDM, SGA) and PP risk factors (weight change, median systolic BP 0-2 weeks PP, resting BP at study visit) will be measured. Ordinary least squares (OLS) regressions will be used to estimate the relationship between Lateral E/e' at 52 weeks and the above risk factors, adjusting for baseline values, to determine if the diastolic function parameters are affected by the risk factors of interest.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2029, 52 months after the start.
Of 191 non-industry observational studies under Pre-Eclampsia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 52 months is above that.
Counting every sponsor, half of 200 studies reached it within 30 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →